Literature DB >> 16960105

Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis.

Frank D Kolodgie1, Allen P Burke, Kristi S Skorija, Elena Ladich, Robert Kutys, Addisalem Taye Makuria, Renu Virmani.   

Abstract

OBJECTIVE: Although lipoprotein-associated phospholipase A2 (Lp-PLA2) has received recent attention as a biomarker of inflammation and risk for acute coronary events, its relative expression in coronary plaque phenotypes, including unstable lesions, has not been established. METHODS AND
RESULTS: Coronary segments (n=30) were prospectively collected from 25 sudden coronary death patients for immunolocalization of Lp-PLA2. Lesion morphologies were classified as pathologic intimal thickening, fibroatheromas, thin-cap fibroatheromas (fibrous cap thicknesses <65 microm), and rupture. The expression of Lp-PLA2 was detected using a specific monoclonal antibody. Apoptosis was identified by DNA end-labeling using terminal deoxynucleotidyl transferase (TdT). Lp-PLA2 staining in early plaques was absent or minimally detected. In contrast, thin-cap fibroatheromas and ruptured plaques showed intense Lp-PLA2 expression within necrotic cores and surrounding macrophages including those in the fibrous cap. The degree of macrophage apoptosis was greater in thin-cap fibroatheroma and ruptures compared with less advanced plaques with additional double labeling studies showing Lp-PLA2 present in apoptotic cells in regions of high macrophage density.
CONCLUSIONS: Lp-PLA2 is strongly expressed within the necrotic core and surrounding macrophages of vulnerable and ruptured plaques, with relatively weak staining in less advanced lesions. These findings together with the association of Lp-PLA2 in apoptotic macrophages suggest a potential role in promoting plaque instability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960105     DOI: 10.1161/01.ATV.0000244681.72738.bc

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  100 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

3.  Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.

Authors:  Harald Grallert; Josée Dupuis; Joshua C Bis; Abbas Dehghan; Maja Barbalic; Jens Baumert; Chen Lu; Nicholas L Smith; André G Uitterlinden; Robert Roberts; Natalie Khuseyinova; Renate B Schnabel; Kenneth M Rice; Fernando Rivadeneira; Ron C Hoogeveen; João Daniel Fontes; Christa Meisinger; John F Keaney; Rozenn Lemaitre; Yurii S Aulchenko; Ramachandran S Vasan; Stephen Ellis; Stanley L Hazen; Cornelia M van Duijn; Jeanenne J Nelson; Winfried März; Heribert Schunkert; Ruth M McPherson; Heide A Stirnadel-Farrant; Bruce M Psaty; Christian Gieger; David Siscovick; Albert Hofman; Thomas Illig; Mary Cushman; Jennifer F Yamamoto; Jerome I Rotter; Martin G Larson; Alexandre F R Stewart; Eric Boerwinkle; Jacqueline C M Witteman; Russell P Tracy; Wolfgang Koenig; Emelia J Benjamin; Christie M Ballantyne
Journal:  Eur Heart J       Date:  2011-10-14       Impact factor: 29.983

4.  Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages.

Authors:  Konstantinos P Markakis; Maria K Koropouli; Stavroula Grammenou-Savvoglou; Ewoud C van Winden; Andromaxi A Dimitriou; Constantinos A Demopoulos; Alexandros D Tselepis; Eleni E Kotsifaki
Journal:  J Lipid Res       Date:  2010-03-23       Impact factor: 5.922

Review 5.  Anti-inflammatory therapies for atherosclerosis.

Authors:  Magnus Bäck; Göran K Hansson
Journal:  Nat Rev Cardiol       Date:  2015-02-10       Impact factor: 32.419

6.  Use of biomarkers to develop treatment strategies for atherosclerosis.

Authors:  Mark A Crandall; Marshall A Corson
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

Review 7.  The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Authors:  Salim S Virani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

8.  Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction.

Authors:  Koto Ishida; Brett Cucchiara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-06

9.  Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.

Authors:  Beth S Sutton; David R Crosslin; Svati H Shah; Sarah C Nelson; Anthony Bassil; A Brent Hale; Carol Haynes; Pascal J Goldschmidt-Clermont; Jeffery M Vance; David Seo; William E Kraus; Simon G Gregory; Elizabeth R Hauser
Journal:  Hum Mol Genet       Date:  2008-01-18       Impact factor: 6.150

10.  Oxidatively modified phosphatidylserines on the surface of apoptotic cells are essential phagocytic 'eat-me' signals: cleavage and inhibition of phagocytosis by Lp-PLA2.

Authors:  V A Tyurin; K Balasubramanian; D Winnica; Y Y Tyurina; A S Vikulina; R R He; A A Kapralov; C H Macphee; V E Kagan
Journal:  Cell Death Differ       Date:  2014-01-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.